SCHEMBL5460352

SCHEMBL5460352

NC(=O)c1c(NC(=O)C2CC2)sc2ccc(NC(=O)Nc3ccc(Br)cc3)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.43
AURKB Q96GD4 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FLT3 P36888 1/20 0.41
DYRK1A Q13627 1/20 0.41
TNIK Q9UKE5 3/20 0.39
MAPK10 P53779 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
EPHX1 P07099 1/20 0.38
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450627 0.90 AURKA (0.50) AURKAAURKBKMT2AMEN1FLT3
SCHEMBL5453459 0.89 AURKA (0.43) AURKAAURKBKMT2AMEN1L3MBTL1
SCHEMBL5467348 0.88 FLT3 (0.47) AURKAAURKBKMT2AMEN1L3MBTL1
SCHEMBL5453182 0.87 MEN1 (0.45) AURKAAURKBKMT2AMEN1FLT3
SCHEMBL5459783 0.79 FLT3 (0.48) AURKAAURKBKMT2AMEN1FLT3
SCHEMBL14361160 0.76 FLT3 (0.44) AURKAAURKBKMT2AMEN1FLT3
SCHEMBL5458832 0.76 MEN1 (0.47) KMT2AMEN1SMN1; SMN2MAPTRAB9A
SCHEMBL5460557 0.75 FLT3 (0.51) AURKAAURKBKMT2AMEN1FLT3
SCHEMBL17611488 0.75 FLT3 (0.46) AURKAAURKBKMT2AMEN1FLT3
SCHEMBL5448452 0.75 NAMPT (0.49) AURKAAURKBKMT2AMEN1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 AURKA 869/4885AURKB 585/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.